For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

EXPLORE THE BIOLOGY

Peptides for Muscle Growth & Growth Hormone: What the Human Evidence Shows

Content updated · how dates work

Growth-hormone pathways and muscle signaling.

This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.

Growth & muscle: what the human evidence shows

Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for growth & muscle: the best trial may be small, negative or about a different condition. No doses.

PeptideStrongest human evidence in our sourcesFDAHuman safety data
FDA-approved medicine (2)Approved for the specific uses on its label, which may not be this goal.
TesamorelinHIV-associated abdominal-fat trial (2007) · Human randomized trial
Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference.
Limitation: Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint.
Studied: 412 people with HIV and abdominal fat accumulation; 86% were men.
FDA-approvedFDA label
VosoritideVosoritide in children with achondroplasia (2020) · Human randomized phase 3 trial
Adjusted annualized growth velocity was 1.57 cm/year higher with vosoritide, with a 95% CI of 1.22–1.93 cm/year.
Limitation: This report did not establish final adult height or long-term functional outcomes. It does not apply to healthy adults with closed growth plates.
Studied: 121 children aged five to under 18 years with achondroplasia.
FDA-approvedFDA label
Randomized human trials (4)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
ACE-031ACE-031 in boys with Duchenne muscular dystrophy (stopped early) (2017) · Human randomized phase 2 trial
ACE-031 was not linked to serious or severe adverse events, but the study was stopped after the second dose level because of nosebleeds and telangiectasias (small dilated blood vessels). Treated boys showed a trend toward keeping their 6-minute walking distance while the placebo group declined, which was not statistically significant, and trends toward more lean mass and bone density and less fat mass.
Limitation: A small safety trial that was stopped early, so the muscle and walking findings are trends, not proof of benefit. Several authors worked for the developer. The side effects that ended the trial were not related to muscle, and the results say nothing in favor of using ACE-031 for muscle building in healthy people.
Studied: Boys with Duchenne muscular dystrophy who could still walk.
Not approvedTrials only
GhrelinGhrelin infusion and food intake (2001) · Human randomized crossover study
Energy intake was approximately 28% higher after ghrelin, and appetite ratings increased. The tested gastric-emptying measure did not change.
Limitation: An acute study in nine healthy people does not establish a chronic disease benefit, sustained weight change, or effects in cachexia.
Studied: Nine healthy volunteers.
Not approvedTrials only
IpamorelinPostoperative ileus proof-of-concept trial (2014) · Human randomized trial
Median time to tolerating a standardized meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p=0.15). Key and secondary efficacy analyses did not show significant between-group differences.
Limitation: Small proof-of-concept study with varied underlying conditions. This setting, route, and endpoint do not test muscle gain, fat loss, sleep improvement, or long-term use.
Studied: 117 patients enrolled after bowel resection; 114 in the safety and modified intention-to-treat populations.
Not approvedTrials only
MK-677Ibutamoren in healthy older adults (2008) · Human randomized trial
Fat-free mass increased with ibutamoren versus placebo, but strength and function did not improve. Fasting glucose increased and insulin sensitivity decreased.
Limitation: More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit.
Studied: 65 healthy adults aged 60–81.
Not approvedTrials only
Small or uncontrolled human studies (7)Human reports without randomization, such as pilots, case series or open-label studies.
CJC-1295Long-acting CJC-1295 (2006) · Human pharmacology trials
Mean growth hormone rose two- to tenfold for at least six days; IGF-1 rose 1.5- to threefold for nine to eleven days after a single exposure. The estimated half-life was 5.8–8.1 days.
Limitation: The endpoints were hormone concentrations. These were studies of long-acting CJC-1295, not proof of muscle gain or equivalence to products labeled “CJC no DAC.”
Studied: Healthy adults aged 21–61.
Not approvedVery limited
Follistatin 344Follistatin-344 listings · eye-harm signal (2020) · Human retrospective case series
Central serous chorioretinopathy was identified. Fluid resolved after an average 2.3 months in eight single-exposure cases; three multiple-exposure cases had recurrence.
Limitation: Referral selection, lack of a denominator, possible confounding, and uncertain product identity prevent estimating incidence or proving causation. It supplies no evidence of muscle-building efficacy.
Studied: 11 male bodybuilding athletes seen at one clinic with reduced vision after injections labeled follistatin-344.
Not approvedNone
GHRP-2Appetite and hormone experiment (2005) · Small human physiology study
Participants ate approximately 36% more during GHRP-2 exposure, and growth-hormone release increased. Every participant ate more in the active condition.
Limitation: An acute meal response in seven men is not evidence for sustained body-composition improvement. Increased appetite may be relevant when interpreting weight-loss marketing.
Studied: Seven lean healthy men.
Not approvedVery limited
GHRP-6Sleep and hormone experiment (1995) · Human physiology experiment
Growth hormone, ACTH, and cortisol increased. Stage-2 sleep increased; slow-wave sleep did not.
Limitation: The response was not restricted to growth hormone. An overnight physiology study does not establish treatment for chronic insomnia, injury recovery, or long-term athletic performance.
Studied: Healthy male volunteers.
Not approvedVery limited
HexarelinEarly healthy-volunteer physiology study (1994) · Human physiology study
Growth hormone rose after hexarelin, peaked at roughly 30 minutes, and returned toward baseline by about 240 minutes.
Limitation: The study did not establish changes in strength, body composition, injury recovery, or long-term clinical outcomes. Twelve volunteers and an acute observation window cannot resolve sustained benefit or safety.
Studied: 12 healthy adult men.
Not approvedVery limited
PEG-MGFNatural MGF after exercise · young vs older men (2003) · Human observational study
MGF messenger RNA rose significantly in the young men but not in the older men.
Limitation: Measures the body's own gene activity, not the effect of taking a synthetic peptide. Small groups.
Studied: 8 young men (25–36) and 7 older men (70–82).
Not approvedNone
SermorelinGeref pediatric growth study (1996) · Human open-label study
Average height velocity increased from 4.1 cm/year at baseline to 7.2 cm/year at 12 months.
Limitation: There was no blinded placebo comparison. Growth in hormone-deficient children cannot establish anti-aging, body-composition, or performance benefits in adults.
Studied: 110 previously untreated children with growth-hormone deficiency; 86 eligible for efficacy analysis.
WithdrawnVery limited
Animal and lab studies only (4)No human study in our sources.
IGF-1 DESSee the profile for the animal and lab research.Not approvedNone
IGF-1 LR3See the profile for the animal and lab research.Not approvedNone
MGFSee the profile for the animal and lab research.Not approvedNone
Modified GRF 1-29See the profile for the animal and lab research.Not approvedNone

Selected studies, not a systematic review. Approval belongs to a specific product and use. Side-by-side comparisons: CJC-1295 vs Ipamorelin · Sermorelin vs Tesamorelin · Ipamorelin vs MK-677 · Tesamorelin vs CJC-1295 (all comparisons).

ACE-031

ACE-031, also called ramatercept, is a large lab-made protein rather than a short peptide. It works as a decoy receptor that binds myostatin and related signals that normally hold back muscle growth. It was tested in boys with Duchenne muscular dystrophy, but that phase 2 trial was stopped early because of nosebleeds and small dilated blood vessels (telangiectasias), and it has never been approved.

Related compounds

Read the studies →

CJC-1295

CJC-1295 is a growth-hormone-releasing-hormone analogue. The foundational human trials studied a long-acting preparation and measured endocrine responses.

Research topics

Read the studies →

Follistatin 344

Follistatin 344 refers to a follistatin precursor isoform. A frequently cited human study delivered an FS344 gene construct using a viral vector; it did not test injections of a supplier’s follistatin protein.

Research topics

Read the studies →

Ghrelin

Ghrelin is a peptide hormone involved in appetite signaling. A small human crossover experiment found higher food intake after an acute infusion.

Research topics

Read the studies →

GHRP-2

GHRP-2 is a synthetic ghrelin-pathway agonist studied for growth-hormone release and eating behavior. Those effects have different practical implications.

Research topics

Read the studies →

GHRP-6

GHRP-6 is a growth-hormone secretagogue with effects extending beyond a single hormone. Human physiology studies help explain that distinction.

Research topics

Read the studies →

Hexarelin

Hexarelin is a synthetic six-residue growth-hormone secretagogue. The selected early human experiment measured hormone release, rather than muscle gain or injury recovery.

Research topics

Read the studies →

IGF-1 DES

Des(1-3) IGF-1 is an IGF-1 analogue missing its first three amino acids. The featured study examined developing rat neural tissue in culture, rather than athletic performance.

Research topics

Read the studies →

IGF-1 LR3

IGF-1 LR3 is a modified IGF-1 analogue. A rat experiment assessed intestinal tissue growth and glucose-analogue absorption, rather than bodybuilding outcomes.

Research topics

Read the studies →

Ipamorelin

Ipamorelin was developed as a growth-hormone secretagogue. Its often-cited selectivity comes from early pharmacology experiments, not a comprehensive human safety program.

Research topics

Read the studies →

MGF

MGF can refer to an IGF-1 splice-product context or a synthetic terminal E-peptide. A primary replication study found no apparent effect of the tested MGF peptides on muscle-cell proliferation or differentiation.

Research topics

Read the studies →

MK-677

MK-677, or ibutamoren, is a small-molecule ghrelin mimetic. A trial in older adults found increased fat-free mass without an improvement in strength or physical function.

Related compounds

Read the studies →

Modified GRF 1-29

Modified GRF 1-29 is a label used for modified growth-hormone-releasing-factor fragments, often described by sellers as “CJC no DAC.” The selected primary study concerns albumin-binding conjugates rather than a confirmed DAC-free preparation.

Research topics

Read the studies →

PEG-MGF

PEG-MGF is a synthetic piece of mechano growth factor, an IGF-1 splice variant that loaded muscle makes, with polyethylene glycol attached to make it last longer. The muscle-growth claim comes from cell studies that a two-company replication could not reproduce, and no published study has tested PEG-MGF itself in cells, animals or people.

Research topics

Read the studies →

Sermorelin

Sermorelin is a growth-hormone-releasing-hormone fragment with a historical pediatric medicine record. That history needs to be distinguished from current wellness marketing.

Research topics

Read the studies →

Tesamorelin

Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.

Prescription medicines

Read the studies →

Vosoritide

Vosoritide is a C-type natriuretic peptide analogue studied for growth in children with achondroplasia. Its disease-specific evidence does not support height-increase claims for healthy adults.

Prescription medicines

Read the studies →

See something wrong on this page? Report a mistake · Corrections

FREE PEPSRADAR ACCOUNT

We check sellers’ lab reports with the testing labs themselves.

So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.

A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.

Create a free accountWhat members get →